文献速递脑血管病外科神经重症

Pipeline栓塞装置治疗前24小时给予600 mg氯吡格雷负荷剂量的安全性与有效性

Safety and Efficacy of a 600-mg Loading Dose of Clopidogrel 24 Hours Before Pipeline Embolization Device Treatment.
PubMed 文献 · World Neurosurg · 2017-07-13

本回顾性队列研究纳入2010年10月至2016年5月接受Pipeline栓塞装置治疗的患者,比较术前24小时给予600 mg氯吡格雷负荷剂量(158例)与常规预处理方案(240例)的安全性和有效性。负荷剂量与改良Rankin量表评分、长期复发、血栓栓塞事件、出血事件及死亡率均无显著关联,作者认为对于不符合标准方案或治疗前血小板抑制率<30%的患者,该负荷剂量应是安全有效的。

要点

  • 术前24小时给予600 mg氯吡格雷负荷剂量与常规预处理相比,改良Rankin量表评分无显著差异(P=0.24)。
  • 负荷剂量与长期复发(OR 1.91;95%CI 0.27-13.50;P=0.52)、血栓栓塞事件(OR 0.99;95%CI 0.96-1.03;P=0.83)及出血事件(OR 1.00;95%CI 0.97-1.03;P=0.99)均无显著关联。
  • 负荷剂量与死亡率无显著关联(OR 1.11;95%CI 0.26-4.65;P=0.89)。

核心结论

  • 在接受Pipeline栓塞装置治疗的队列中,对于不符合标准方案或治疗前血小板抑制率<30%的患者,600 mg氯吡格雷负荷剂量应是安全有效的。

研究设计与样本

  • 回顾性队列研究,纳入2010年10月至2016年5月接受Pipeline栓塞装置治疗的患者。
  • 39.7%(n=158)的患者在装置置入前24小时接受650 mg阿司匹林加至少600 mg氯吡格雷负荷剂量;60.3%(n=240)的患者术前接受每日81-325 mg阿司匹林共10天联合每日75 mg氯吡格雷。
  • 平均随访15.8个月(标准差12.4个月),采用多变量logistic回归和倾向评分匹配控制混杂。

主要发现

  • 398例患者中,两组女性比例均约16.5%(41/240),平均年龄均约56.46岁;约12.2%(均值=0.09;标准差=0.30)有蛛网膜下腔出血。
  • 预处理组92%(均值=0.29;标准差=0.70)和负荷剂量组85.7%(均值=0.44;标准差=0.91)的患者改良Rankin量表评分≤2。
  • 多变量分析中,负荷剂量不影响改良Rankin量表评分,P=0.24。
  • 7例患者出现长期复发,其中预处理组2例(0.83%;均值=0.01;标准差=0.10)。
  • 多变量logistic回归中,负荷剂量与长期复发率(OR 1.91;95%CI 0.27-13.50;P=0.52)、血栓栓塞事件(OR 0.99;95%CI 0.96-1.03;P=0.83)及出血事件(OR 1.00;95%CI 0.97-1.03;P=0.99)均无显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device (PED) treatment. METHODS: We performed a retrospective cohort study involving patients treated with pipeline from October 2010 to May 2016. A total of 39.7% (n = 158) of patients were dispensed a loading dose of 650 mg of aspirin plus at least 600 mg of clopidogrel 24 hours preceding PED deployment; 60.3% (n = 240) received 81-325 mg of aspirin daily for 10 days with 75 mg of clopidogrel daily preprocedurally. The mean follow-up was 15.8 months (standard deviation [SD] 12.4 months). modified Rankin Scale (mRS) was registered before the discharge and at each follow-up visit. To control confounding, we used multivariable logistic regression and propensity score conditioning. RESULTS: Of 398 patients, the proportion of female patients was ≈16.5% (41/240) in both groups and shared the same mean of age ≈56.46 years. Similarly, ≈12.2% (mean = 0.09; SD = 0.30) had a subarachnoid hemorrhage. A total of 92% (mean = 0.29; SD = 0.70) from the pretreatment group and 85.7% (mean = 0.44; SD = 0.91) of the bolus group had a mRS ≤2. In a multivariate analysis, bolus did not affect the mRS score, P = 0.24. Seven patients had a long-term recurrence, 2 (0.83%; mean = 0.01; SD = 0.10) from the pretreatment group. In a multivariable logistic regression, bolus was not associated with a long-term recurrence rate (odds ratio [OR] 1.91; 95% confidence interval [CI] 0.27-13.50; P = 0.52) neither with thromboembolic accidents (OR 0.99; 95% CI 0.96-1.03; P = 0.83) nor with hemorrhagic events (OR 1.00; 95% CI 0.97-1.03; P = 0.99). Three patients died: 1 who received a bolus had an acute subarachnoid hemorrhage. The mean mortality rate was parallel in both groups ≈0.25 (SD = 0.16). Bolus was not associated with mortality (OR 1.11; 95% CI 0.26-4.65; P = 0.89). The same associations were present in propensity score-adjusted models. CONCLUSIONS: In a cohort receiving PED, a 600-mg loading dose of clopidogrel should be safe and efficacious in those off the standard protocol or showing <30% platelet inhibition before treatment.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Atallah E, Saad H, Bekelis K, et al. Safety and Efficacy of a 600-mg Loading Dose of Clopidogrel 24 Hours Before Pipeline Embolization Device Treatment. World Neurosurg. 2017. PMID: 28712897. doi:10.1016/j.wneu.2017.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。